Last reviewed 2026-04-23 · How we verify

AZD6094

AZD6094 is a small molecule inhibitor of the CD73 enzyme.

AZD6094 is a small molecule inhibitor of the CD73 enzyme. Used for Metastatic non-small cell lung cancer, Metastatic melanoma.

At a glance

Mechanism of action

CD73 is an enzyme involved in the production of adenosine, which plays a role in immune suppression. By inhibiting CD73, AZD6094 aims to reduce adenosine levels and enhance anti-tumor immune responses.

Approved indications

• Metastatic non-small cell lung cancer
• Metastatic melanoma

Common side effects

• Fatigue
• Nausea
• Diarrhea

Key clinical trials

• Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib (PHASE2)
• AZD9291 in Combination With Ascending Doses of Novel Therapeutics (PHASE1)
• Savolitinib vs. Sunitinib in MET-driven PRCC. (PHASE3)
• Ph2 Study of Savolitinib and Durvalumab (MEDI4736) Combination in Advanced MET Amplified Gastric Cancer(VIKTORY-2) (PHASE2)
• Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC (PHASE3)
• Volitinib in Treating Patients With Recurrent or Refractory Primary CNS Tumors (PHASE1)
• Testing Cabozantinib, Crizotinib, Savolitinib and Sunitinib in Kidney Cancer Which Has Progressed (PHASE2)
• Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.